Hansoh Pharmaceutical Group Company Limited
3692
Peringkat dalam Saham
#903
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Harga Saham
$4.38
Kapitalisasi Pasar
$26.56B
Perubahan (1 hari)
-0.38%
Perubahan (1 tahun)
-5.15%
Negara
CN
Perdagangan Hansoh Pharmaceutical Group Company Limited (3692)
Kategori
Healthcare
Pendapatan untuk Hansoh Pharmaceutical Group Company Limited (3692)
Pendapatan pada Jun 2026 TTM: $2.30B
Menurut laporan keuangan terbaru dari Hansoh Pharmaceutical Group Company Limited, pendapatan saat ini (TTM) adalah $2.30B. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $1.43B peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar $1.36B. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Hansoh Pharmaceutical Group Company Limited dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $2.30B | 37.16% |
| 2024 | $1.68B | 17.68% |
| 2023 | $1.43B | 4.94% |
| 2022 | $1.36B | -12.98% |
| 2021 | $1.56B | 17.51% |
| 2020 | $1.33B | 6.68% |
| 2019 | $1.25B | 11.07% |
| 2018 | $1.12B | 18.09% |
| 2017 | $950.71M | 21.49% |
| 2016 | $782.52M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 186.97% |
IN
|
